What is vaginal cytology and how to detect vaginal infections?

Vaginal cytology, most commonly performed as the Papanicolaou (Pap) test or Pap smear, is a cytologic screening procedure used primarily to detect cellular abnormalities of the cervix that may indicate precancerous changes or cancer. In addition to its principal role in cervical cancer screening, cytologic specimens can occasionally show changes suggestive of inflammation or infection. However, targeted testing — including microbiologic cultures, nucleic acid amplification tests (NAATs), and point-of-care microscopy — is usually required to accurately diagnose vaginal or sexually transmitted infections (STIs). This article reviews the purpose, technique, interpretation, limitations, and follow‑up of vaginal cytology, and summarizes how common vaginal infections are diagnosed and managed in clinical practice.

Sources cited in the text include professional organizations and authoritative clinical resources (American College of Obstetricians and Gynecologists [ACOG], National Institutes of Health [NIH], Mayo Clinic, Cleveland Clinic). For detailed, individualized recommendations, patients should consult their healthcare provider.

Overview: purpose of vaginal cytology (Pap test)

Primary purpose: screen for cervical precancer (cervical intraepithelial neoplasia) and invasive cervical cancer by detecting abnormal epithelial cells from the transformation zone of the cervix.
Secondary observations: cytology may show inflammatory changes, presence of fungal elements, or organisms that occasionally are visible on slides (for example, trichomonads or yeast), but the Pap test is not the most sensitive or specific method for diagnosing infectious vaginitis.
Additional tests: Human papillomavirus (HPV) testing (either co‑testing with cytology or primary HPV testing) has become central to cervical cancer prevention because specific high‑risk HPV types are the causal factor for most cervical cancers (ACOG; NIH) (ACOG patient resources, NIH/MedlinePlus on Pap tests and HPV).

Types of cytologic methods

Conventional (fixed) Pap smear: cells are collected on a glass slide, fixed, and sent to the laboratory.
Liquid‑based cytology (LBC): cells are collected and placed into a preservative fluid; part of the specimen can be used for cytology and part reserved for HPV testing or other molecular assays. LBC has largely replaced conventional smears in many settings because of ease of processing and the ability to perform reflex HPV testing (Mayo Clinic; Cleveland Clinic).

Who should be screened and when — current screening guidelines

Screening recommendations have been standardized by organizations such as ACOG and the U.S. Preventive Services Task Force (USPSTF). Common contemporary recommendations include:

Begin screening at age 21 years with cytology alone every 3 years for ages 21–29.
For ages 30–65, options include:
Cytology alone every 3 years, or
Co‑testing with cytology plus HPV testing every 5 years, or
Primary HPV testing alone every 5 years (depending on availability and local guidance).
Discontinue routine screening after age 65 if prior adequate negative screening and no history of high‑grade lesions (ACOG; USPSTF) (ACOG practice resources, NIH/MedlinePlus screening overview).
Women with immunosuppression, history of cervical dysplasia, exposure to diethylstilbestrol (DES), or other risk factors may require different surveillance schedules.

Note: Guidelines are periodically updated. Always refer to the current guidance from ACOG, USPSTF, or local public health authorities for the most up‑to‑date recommendations.

Preparing for a Pap test — practical advice

To maximize the accuracy of cervical cytology and HPV testing, clinicians commonly advise patients to follow simple pretest instructions:

Timing relative to menses: ideally schedule the test when not menstruating; many clinicians prefer waiting 4–5 days after the end of menstrual bleeding. If bleeding is present, testing may still be performed if clinically appropriate (Mayo Clinic).
Avoid vaginal intercourse, douches, vaginal creams, spermicides, or intravaginal medications for 24–48 hours before the test, as these may alter cytology or interfere with HPV testing.
Avoid use of tampons for 24–48 hours prior to collection.
Inform the clinician if pregnant, immunosuppressed, or if there is a history of abnormal screening results.

These measures help reduce artifacts and false‑negative or indeterminate results (Cleveland Clinic; Mayo Clinic).

The procedure — what to expect

During a routine cervical cytology collection:

The patient lies in the lithotomy position with feet in stirrups.
A sterile speculum is gently introduced into the vagina to visualize the cervix. Warmed water‑based lubricant may be used externally but clinicians often avoid lubricants on the speculum because they can interfere with specimen quality.
The transformation zone of the cervix — where the ectocervical and endocervical epithelium meet — is sampled using a cervical brush, spatula, or broom‑type device. Separate endocervical sampling may be obtained using an endocervical brush or cytobrush.
Samples are either smeared on a slide (conventional Pap) or rinsed into a preservative liquid (LBC) for laboratory processing.
A small portion of the specimen can be used for HPV testing or other molecular assays as indicated.

Most patients experience only mild discomfort. If severe pain occurs, the clinician will assess and modify the approach.

Laboratory processing and reporting — the Bethesda System

Cytology results are reported using a standardized system (Bethesda System), which facilitates management decisions. Major categories include:

Negative for intraepithelial lesion or malignancy (normal).
Epithelial cell abnormalities:
Atypical squamous cells of undetermined significance (ASC‑US)
Atypical squamous cells—cannot exclude HSIL (ASC‑H)
Low‑grade squamous intraepithelial lesion (LSIL)
High‑grade squamous intraepithelial lesion (HSIL)
Atypical glandular cells (AGC)
Suspicious for carcinoma or carcinoma
Other findings: organisms such as yeast, trichomonads, and bacterial vaginosis (clue cells) or marked inflammation may be commented upon but are not considered diagnostic without corroborating microbiologic tests.

Laboratories often reflex to HPV testing when ASC‑US or other specific cytologic findings are reported (ACOG).

Interpretation and follow‑up of abnormal results

Management depends on age, cytology category, and HPV status.

ASC‑US:
Age 21–24: repeat cytology in 12 months is common.
Age ≥25: reflex HPV testing is often performed. If HPV positive, referral for colposcopy may be recommended; if HPV negative, repeat cytology at an interval is typical (ACOG).
LSIL:
Many clinicians proceed to colposcopy (visual examination of the cervix with magnification) because LSIL can represent HPV‑associated changes.
HSIL:
Prompt colposcopy and usually biopsy are recommended because HSIL has a higher likelihood of underlying precancer.
AGC:
Requires careful evaluation including colposcopy, endocervical sampling, and sometimes endometrial assessment depending on age and risk factors.

Colposcopy and biopsy are the diagnostic steps to establish histologic grade and guide treatment if cytology is abnormal. Histologic results (CIN 1, CIN 2, CIN 3) determine treatment thresholds (ACOG practice bulletins).

Limitations of Pap cytology

Sensitivity and specificity: Pap cytology has high specificity for high‑grade lesions but variable sensitivity; false negatives can occur due to sampling error, obscuring blood/inflammation, or interpretive error.
Not a diagnostic test: Cytology is a screening test; abnormal results require diagnostic evaluation (colposcopy and biopsy).
Limited detection of some infections: Although cytology can occasionally show organisms or inflammatory changes, it is not the preferred method to diagnose most vaginitis or STIs. For example, chlamydia and gonorrhea are usually diagnosed via NAAT; trichomonas is best detected by NAAT or microscopy; bacterial vaginosis is a clinical/microscopic diagnosis (NIH; Mayo Clinic).

How are vaginal infections diagnosed?

Vaginal symptoms are common and have multiple causes. Diagnosis depends on clinical history, physical examination, and targeted laboratory testing.

Common causes of vaginal symptoms

Bacterial vaginosis (BV)
Vulvovaginal candidiasis (yeast infection)
Trichomoniasis
Atrophic vaginitis (postmenopausal)
Sexually transmitted infections (Chlamydia trachomatis, Neisseria gonorrhoeae)
Noninfectious causes (allergic contact dermatitis, foreign body)

Clinical evaluation

History: nature of discharge (quantity, color), odor, onset, itching, irritation, dysuria, recent antibiotic use, sexual exposures, contraceptive methods, menstrual pattern, and menopausal status.
Examination: assessment of vulvar skin, vaginal mucosa, and cervix; note odor (whiff test), discharge characteristics, and pH of vaginal fluid (normal vaginal pH ≤4.5).

Office tests and samples

Vaginal pH testing: elevated pH (>4.5) is common in BV and trichomoniasis, less likely in candidiasis.
Wet mount (saline microscopy): allows visualization of motile trichomonads, pseudohyphae or budding yeast, and clue cells (epithelial cells coated with bacteria) suggestive of BV. Amsel criteria for BV include homogeneous discharge, positive whiff test, clue cells, and pH >4.5.
Potassium hydroxide (KOH) preparation: dissolves epithelial cells and bacteria, accentuates yeast or pseudohyphae and produces an "amine" (fishy) odor in BV when combined with the whiff test.
NAATs: highly sensitive and specific for Trichomonas vaginalis, Chlamydia trachomatis, and Neisseria gonorrhoeae; many laboratories now offer multiplex panels.
Vaginal culture: less commonly used for routine vaginitis but may be used for refractory or atypical infections.
Point‑of‑care tests: some clinics use rapid antigen or molecular tests for trichomonas and other pathogens.

Because the Pap test may not identify all pathogens or may miss active infection, clinicians usually obtain targeted tests based on clinical suspicion (Mayo Clinic; Cleveland Clinic).

Typical diagnostic patterns for common vaginal conditions

Bacterial vaginosis:
Symptoms: thin, homogeneous, grayish discharge with fishy odor (may be noticed after intercourse).
Findings: clue cells on microscopy, positive whiff test, vaginal pH >4.5.
Diagnosis: clinical criteria (Amsel) or Nugent score on Gram stain; NAATs are not routinely required for BV.
Vulvovaginal candidiasis:
Symptoms: pruritus, thick white "cottage cheese" discharge, irritation.
Findings: pseudohyphae or budding yeast on KOH/wet mount; pH typically normal (≤4.5).
Trichomoniasis:
Symptoms: frothy yellow/green discharge, odor, vulvar irritation; many infections are asymptomatic.
Findings: mobile flagellated organisms on wet mount (microscopy), elevated pH; NAAT has higher sensitivity.
Note: trichomoniasis is an STI and warrants partner treatment and STI screening.
Atrophic vaginitis (postmenopausal):
Symptoms: dryness, burning, dyspareunia, thin watery discharge.
Findings: pale, thin vaginal mucosa; cytology may show atrophic changes and increased parabasal cells (vaginal atrophy).
Management often includes local estrogen therapy when appropriate.

Role of Pap cytology in detecting infections

Pap smears may occasionally report organisms (e.g., Candida, trichomonads, or clue cells), but these findings are neither as sensitive nor as specific as targeted diagnostic tests.
If cytology suggests an infectious process (marked inflammation or visible organisms), clinicians will usually obtain confirmatory microbiologic testing.
For symptomatic patients, reliance solely on Pap results is not appropriate; directed evaluation is necessary (NIH; Mayo Clinic).

Treatment principles for common vaginal infections

Treatment should be guided by a confirmed or strongly suspected diagnosis, host factors (pregnancy, allergy, immunosuppression), and national guidelines. Below are general principles; specific regimens and doses should be confirmed with current clinical guidelines (for example, CDC STI treatment guidelines) and individual patient factors.

Bacterial vaginosis:
Common first‑line options include oral metronidazole or topical metronidazole gel or clindamycin cream. Recurrent BV may require longer or suppressive regimens.
Vulvovaginal candidiasis:
First‑line therapy often includes single‑dose oral fluconazole or topical azole antifungals (clotrimazole, miconazole) for several days.
Trichomoniasis:
Oral metronidazole or tinidazole is standard; partner treatment is essential to prevent reinfection. NAAT testing improves diagnostic sensitivity.
Chlamydia and gonorrhea:
These STIs are usually diagnosed by NAAT and require systemic antibiotic therapy per STI treatment guidelines; partner notification and treatment are important.

Because therapeutic recommendations evolve, clinicians should consult up‑to‑date resources. The CDC and specialty societies provide current treatment algorithms for STIs and vaginitis.

Special situations

Pregnancy:
Pap testing is safe during pregnancy if indicated; management of abnormal results may differ (colposcopy is generally safe in pregnancy when indicated).
Some infections (e.g., BV, trichomonas, chlamydia, gonorrhea) in pregnancy may have obstetric implications and typically warrant treatment using recommended regimens for pregnancy (consult obstetric care providers and CDC guidance).
Postmenopausal women:
Vaginal symptoms may reflect atrophy rather than infection; review hormonal status and consider local estrogen therapy after evaluating risks and benefits.
Immunocompromised patients (including HIV):
Screening frequency and management thresholds may differ; more vigilant surveillance is often indicated (ACOG).

When to see a healthcare provider

Seek clinical evaluation if any of the following occur:

New or persistent vaginal discharge, especially if associated with odor, itching, bleeding, pain, or urinary symptoms.
Pain during intercourse or unexplained pelvic pain.
Known exposure to an STI or a new sexual partner.
Abnormal Pap test result that requires follow‑up.
Pregnancy with symptoms of infection.

Early evaluation allows appropriate testing, diagnosis, and treatment to reduce complications and transmission.

Follow‑up after abnormal cytology or infection

Abnormal cytology: follow established algorithms (colposcopy, HPV testing, repeat cytology, or biopsy as indicated). Many Healthcare systems have recall systems to ensure follow‑up; patients should verify they have appropriate appointments.
Infections: confirm cure when indicated (e.g., test of cure for trichomoniasis may be recommended) and ensure partners receive treatment when necessary to prevent reinfection.
Recurrent or refractory symptoms warrant further evaluation for alternative diagnoses, resistance, or compliance issues.

Advances and emerging approaches

Primary HPV testing and molecular assays: HPV testing is increasingly used either alone (primary HPV screening) or in combination with cytology (co‑testing), because HPV infection is the primary driver of cervical cancer risk (ACOG; NIH).
Self‑collected vaginal samples for HPV and some NAATs: emerging evidence supports self-collection as an acceptable alternative for some screening programs and may improve screening uptake; however, clinical pathways for self‑collection vary by location and test availability.
Point‑of‑care molecular diagnostics: higher sensitivity rapid tests for trichomonas and other pathogens are increasingly available and improve clinic‑based diagnosis.

Pitfalls and patient counseling points

A normal Pap test does not exclude sexually transmitted infections or guarantee lifetime protection from cervical cancer; screening schedules should be followed.
A single abnormal Pap does not necessarily mean cancer — many abnormalities reflect transient HPV infection or low‑grade changes that may regress.
HPV vaccination significantly reduces the risk of persistent infection with vaccine‑preventable HPV types and subsequent cervical precancer; vaccination is recommended according to age‑based guidelines and remains an important preventive measure in cervical cancer control strategies (NIH; ACOG).
Patients should be encouraged to keep follow‑up appointments and complete recommended diagnostic or treatment regimens. Clinicians should communicate results and next steps clearly.

Summary

Vaginal cytology (Pap testing) is a cornerstone of cervical cancer screening designed to detect epithelial abnormalities that may evolve into cancer. While cytologic findings can sometimes suggest infectious or inflammatory processes, the Pap test is not the optimal diagnostic modality for most vaginal infections. Targeted testing — wet mount microscopy, pH testing, KOH preparation, NAATs, and cultures — provides a more accurate diagnosis of common causes of vaginitis such as bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis. Abnormal cytology requires appropriate follow‑up (HPV testing, colposcopy, biopsy) according to standardized algorithms. For persistent symptoms, atypical findings, pregnancy, or immunosuppression, individualized assessment is essential. For current screening and management recommendations, consult ACOG, NIH/MedlinePlus, Mayo Clinic, and Cleveland Clinic resources and discuss personal risk and management with your healthcare provider.

Selected resources and further reading:

American College of Obstetricians and Gynecologists (ACOG) practice bulletins and patient resources: https://www.acog.org
National Institutes of Health / MedlinePlus — Pap test overview and HPV information: https://medlineplus.gov
Mayo Clinic — Pap test information and vaginitis overview: https://www.mayoclinic.org
Cleveland Clinic — Vaginitis and cervical screening explanations: https://my.clevelandclinic.org

(For specific therapeutic regimens, diagnostic algorithms, and up‑to‑date clinical guidance, clinicians and patients should consult current CDC STI treatment guidelines, local public health recommendations, and specialty society practice bulletins.)